Blood: Bleeding and thromboembolism risk and predictive markers in newly crowned virus-infected people

Increased D-dipolymer levels in patients with neo-coronavirus (
COVID-19)Early reports suggest that patients with new crown virusinfection sedituatedhave a higher incidence of venousthrombosisembolism (VTE) and diffuseintravascularintra-blood clotting (DIC), but no clear data are availablethis study is a multi-center retrospective study designed to assess the incidence and severity of hemorrhoid and thrombosis complications in 400 hospitalized COVID-19 patients (including 144 critically ill patients) who used standard dosesprevent
anticoagulantThe blood clotting and inflammatory parameters of patients with or without coagulation-related complications were comparedmultivariate logistic model tested the effectiveness of these markers in predicting coagulation-related complications, critical illness, and deaththe imaging-confirmed rate of venous thromboembolism was 4.8% (95% CI, 2.9-7.3%), and the total incidence of thrombosis complications was 9.5% (6.8-12.8%) The total hemorrhage rate and hemorrhage rate were 4.8% (2.9-7.3%) and 2.3% (1.0-4.2%) respectively In critically ill patients, the imaging-confirmed VTE and haemorrhage rates were 7.6% (3.9-13.3%) and 5.6% (2.4-10.7%), respectively the increase in D-dimathin during initial hospitalization predicts blood clotting-related complications during hospitalization (D-and-polysis 2500 ng/ml), thrombosis correction OR is 6.79 (2.39-19.30), or hemorrhage OR is 3.56 (1.01-12.66)," critical illness and risk of death Other predictable signs of blood clot risk during hospitalization were: plateplate count , 450 x 109/L (corrected OR for 3.56 ,1.27-9.97), C-Reactive Protein (CRP) , 100 mg/L (2.71 ,26-5.86) and erythropoietic deposition rate of 40 mm/h (2.71.86)) EsR, CRP, fibrino, heteroproteinand and calcitonin in patients with thrombosis complications were higher than in patients with no thrombosis complications DIC, clinically associated platelet reduction and fibrinogen reduction are very rare, accompanied by significant bleeding manifestations Given the observed rate of bleeding, randomized trials are needed to determine any potential benefits for patients with COVID-19 that enhance anticoagulant prevention